As our results are the first to reveal that low-dose crizotinib monotherapy can be an effective repositioned-drug monotherapy for P-gp-overexpressing drug-resistant cancer, our findings also suggest a role for crizotinib in the prevention or reduction of drug-resistant cancer in clinic. The gene discussed is PGP; the disease is cancer.